deltatrials
Completed PHASE4 NCT00347100

Insulin Glargine in Type 2 Diabetic Patients

Treatment of Early Insulinization With Glargine in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea or Metformin Monotherapy

Sponsor: Sanofi

Conditions Diabetes Mellitus, Type 2
Interventions Glimiperide Glipizide Glyburide Glyclazide Insulin Glargine Metformin
Updated 5 times since 2017 Last updated: Sep 14, 2009 Started: Jun 30, 2006 Primary completion: May 31, 2008

This PHASE4 trial investigates Diabetes Mellitus, Type 2 and is currently completed. Sanofi leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sanofi
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Beijing, China